Orthocell Achieves First Remplir Sales in Thailand

Key points

• First commercial sales of Remplir in the US$84 million Thai nerve repair market
• Sales follow Thai FDA approval and partnership with MediTime
• Thailand is a key market in Asia for Orthocell's global growth strategy

Full summary

Orthocell Ltd, a regenerative medicine company, announced the first commercial sales of its nerve repair product, Remplir, in Thailand. This milestone extends Remplir's commercial presence in Asia and establishes a pathway into a strategically important market with a sophisticated healthcare system and significant market potential. The sales follow Thai FDA approval and the appointment of MediTime as the Company's exclusive in-country distributor for Remplir in Thailand. MediTime is a specialist orthopaedics and sports medicine distributor with established coverage across leading hospitals, medical schools and regional centres in Thailand.

Outlook

Orthocell sees significant potential for growth in Thailand over the medium to longer term.